Tang Capital Management LLC
Tang Capital Management LLC reported 45 holdings worth US$2.17B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Tang Capital Management LLC reported 45 holdings worth US$2.17B as of Sep 30, 2026. Largest: Aurinia Pharmaceuticals Inc, Corcept Therapeutics Incorporated and Spyre Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 45
- Value as reported
- US$2.17B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Aurinia Pharmaceuticals Inc | 13M | US$211M | 9.7% |
| Corcept Therapeutics Incorporated | 1.5M | US$173M | 8.0% |
| Spyre Therapeutics, Inc. | 1.89M | US$168M | 7.7% |
| Tarsus Pharmaceuticals, Inc. | 1.92M | US$151M | 6.9% |
| Lakefront Biotherapeutics | 3.99M | US$118M | 5.4% |
| Celcuity Inc. | 1.46M | US$116M | 5.4% |
| Mirum Pharmaceuticals, Inc. | 1.24M | US$106M | 4.9% |
| PTC Therapeutics, Inc. | 1.5M | US$97.2M | 4.5% |
| Immunocore Holdings plc | 2.88M | US$87.4M | 4.0% |
| AnaptysBio, Inc. | 1.47M | US$74.1M | 3.4% |
| State Street SPDR S&P 500 ETF | 95,000 | US$72.4M | 3.3% |
| COMPASS Pathways Plc | 5.2M | US$64.7M | 3.0% |
| Precigen, Inc. | 6.42M | US$54.9M | 2.5% |
| ANI Pharmaceuticals, Inc. | 708K | US$51.4M | 2.4% |
| BioNTech SE | 470K | US$46.2M | 2.1% |
| Viridian Therapeutics, Inc. | 1.79M | US$36.9M | 1.7% |
| Nuvectis Pharma, Inc. | 1.58M | US$33.3M | 1.5% |
| Nano Dimension Ltd | 20.9M | US$32.9M | 1.5% |
| Ardelyx, Inc. | 9.05M | US$30.9M | 1.4% |
| Fulcrum Therapeutics, Inc. | 7.08M | US$26.2M | 1.2% |
| Atea Pharmaceuticals, Inc. | 4.81M | US$25.1M | 1.2% |
| Dianthus Therapeutics, Inc. | 265K | US$23.3M | 1.1% |
| Compass Therapeutics, Inc. | 18M | US$18.7M | 0.86% |
| Nuvation Bio Inc. | 3.3M | US$18.5M | 0.85% |
| IDEAYA Biosciences, Inc. | 450K | US$17.3M | 0.80% |
| Crescent Biopharma, Inc. | 1.16M | US$16.9M | 0.78% |
| Viking Therapeutics, Inc. | 500K | US$16.3M | 0.75% |
| Vera Therapeutics, Inc. | 500K | US$16.1M | 0.74% |
| Legend Biotech Corp. | 700K | US$13.9M | 0.64% |
| PMV Pharmaceuticals, Inc. | 7.29M | US$12.2M | 0.56% |
| Insmed Incorporated | 100K | US$11.4M | 0.53% |
| Journey Medical Corporation | 1.61M | US$11M | 0.51% |
| Moderna, Inc. | 50,000 | US$9.63M | 0.44% |
| Stoke Therapeutics, Inc. | 300K | US$7.8M | 0.36% |
| Boundless Bio, Inc. | 2.84M | US$7.13M | 0.33% |
| Pliant Therapeutics, Inc. | 6.14M | US$6.63M | 0.31% |
| Heron Therapeutics, Inc. | 8.97M | US$2.81M | 0.13% |
| Altimmune, Inc. | 666K | US$1.9M | 0.09% |
| LENZ Therapeutics, Inc. | 451K | US$1.73M | 0.08% |
| Sionna Therapeutics, Inc. | 125K | US$658K | 0.03% |
| Rocket Pharmaceuticals, Inc. | 100K | US$263K | 0.01% |
| Capricor Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related